BioCryst Pharmaceuticals Inc BCRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
BioCryst to Present at Upcoming Investor Conferences
BioCryst Reports Third Quarter 2026 Financial Results
BioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
BioCryst to Report Third Quarter 2026 Financial Results on November 4
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth
BioCryst to Present at Upcoming Investor Conference
BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan
BioCryst Gets FDA OK for Pediatric Use of Orladeyo
Trading Information
- Previous Close Price
- $7.65
- Day Range
- $7.48–7.78
- 52-Week Range
- $6.27–11.20
- Bid/Ask
- $7.69 / $7.70
- Shares Outstanding
- 257.30M
- Market Cap
- $1.99B
- Volume/Avg
- 2M / 5M
Key Statistics
- Price/Earnings (Normalized)
- 5.28
- Price/Sales
- 1.93
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 435
- Website
- https://www.biocryst.com
Valuation
Metric | BCRX |
|---|---|
Price/Earnings (Normalized) | 5.28 |
Price/Book Value | — |
Price/Sales | 1.93 |
Price/Cash Flow | 3.92 |
Price/Earnings
BCRX
Financial Strength
Metric | BCRX |
|---|---|
Quick Ratio | 2.54 |
Current Ratio | 2.71 |
Interest Coverage | −3.76 |
Quick Ratio
BCRX
Profitability
Metric | BCRX |
|---|---|
Return on Assets (Normalized) | 41.94% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | 84.63% |
Return on Assets
BCRX
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|nt!qGxp | LOCK|p^dW | $74B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|Q^K$$px> | LOCK|KdZz | $50B | |||
| Haleon PLC ADR HLN | LOCK|c%GK%pQ | LOCK|QD | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|%?>Jx?Z | LOCK|Z? | $34B | |||
| Viatris Inc VTRS | LOCK|pwt?@>? | LOCK|yX | $24B | |||
| Elanco Animal Health Inc ELAN | LOCK|@W | LOCK|$J | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|<&<lH%m | LOCK|?V> | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|l$?sxh | LOCK|R# | $5B | |||
| Perrigo Co PLC PRGO | LOCK|bDsqP? | LOCK|G&$ | $2B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|P<nzSB | LOCK|c@QcJ | $2B |
United States